Nieman David C, Henson Dru A, Dumke Charles L, Oley Kevin, McAnulty Steven R, Davis J Mark, Murphy E Angela, Utter Alan C, Lind Robert H, McAnulty Lisa S, Morrow Jason D
Department of Health, Leisure, and Exercise Science, Fischer Hamilton/Nycom Biochemistry Laboratory, Appalachian State University, Boone, NC 28608, USA.
Brain Behav Immun. 2006 Nov;20(6):578-84. doi: 10.1016/j.bbi.2006.02.001. Epub 2006 Mar 22.
The primary purpose of this study was to measure the influence of ibuprofen use during the 160-km Western States Endurance Run on endotoxemia, inflammation, and plasma cytokines. Subjects included 29 ultramarathoners who consumed 600 and 1200 mg ibuprofen the day before and on race day, respectively, and 25 controls that competed in the race but avoided ibuprofen and all other medications. Blood and urine samples were collected the morning prior to and immediately following the race, and subjects recorded muscle soreness during the week following the race using a 10-point Likert scale (DOMS). Race time (25.8+/-.6 and 25.6+/-.8 h, respectively) and ratings of perceived exertion (RPE, 6-20 scale) (14.6+/-.4 and 14.5+/-.2, respectively) did not differ significantly between ibuprofen users and nonusers. Ibuprofen use compared to nonuse was linked to a smaller increase in urine creatinine (P=.038), higher plasma levels of lipopolysaccharide (group effect, P=.042), and greater increases (pre-to-post race) in serum C-reactive protein and plasma cytokine levels for interleukin (IL)-6, IL-10, IL-8, IL-1 ra, granulocyte colony-stimulating factor, monocyte chemotactic protein 1, and macrophage inflammatory protein 1 beta, but not tumor necrosis factor alpha. Post-race DOMS and serum creatine kinase levels did not differ significantly between ibuprofen users and nonusers (20,621+/-3565 and 13,886+/-3068 microcal/L, respectively, P=.163). In conclusion, ibuprofen use compared to nonuse by athletes competing in a 160-km race did not alter muscle damage or soreness, and was related to elevated indicators of endotoxemia and inflammation.
本研究的主要目的是测量在160公里的西部各州耐力跑期间使用布洛芬对内毒素血症、炎症和血浆细胞因子的影响。受试者包括29名超级马拉松运动员，他们分别在比赛前一天和比赛当天服用了600毫克和1200毫克布洛芬，以及25名参加比赛但避免使用布洛芬和所有其他药物的对照组。在比赛前一天早晨和比赛结束后立即采集血液和尿液样本，受试者在比赛后的一周内使用10分制李克特量表（DOMS）记录肌肉酸痛情况。布洛芬使用者和非使用者之间的比赛时间（分别为25.8±0.6小时和25.6±0.8小时）和自觉用力程度评分（RPE，6-20分制）（分别为14.6±0.4和14.5±0.2）没有显著差异。与未使用布洛芬相比，使用布洛芬与尿肌酐增加幅度较小（P=0.038）、血浆脂多糖水平较高（组效应，P=0.042）以及血清C反应蛋白和血浆细胞因子水平（白细胞介素（IL）-6、IL-10、IL-8、IL-1受体拮抗剂、粒细胞集落刺激因子、单核细胞趋化蛋白1和巨噬细胞炎性蛋白1β，但不包括肿瘤坏死因子α）在比赛前后的增加幅度较大有关。布洛芬使用者和非使用者之间的赛后DOMS和血清肌酸激酶水平没有显著差异（分别为20621±3565和13886±3068微卡/升，P=0.163）。总之，在160公里比赛中，与未使用布洛芬的运动员相比，使用布洛芬并未改变肌肉损伤或酸痛情况，且与内毒素血症和炎症指标升高有关。
